Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Not Yet Opened 06-10 16:00:00 EDT

3.20

-0.19

-5.60%

盘后3.30

+0.10+3.12%

19:46 EDT

High3.52	Low3.15	Vol120.50K
Open3.37	D1 Closing3.39	Amplitude10.86%
Mkt Cap3.26M	Tradable Cap3.25M	Total Shares1.02M
T/O399.53K	T/O Rate11.88%	Tradable Shares1.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":3.2,"timestamp":1781121600000,"preClose":3.39,"halted":0,"volume":120501,"hourTrading":{"tag":"盘后","latestPrice":3.3,"preClose":3.2,"latestTime":"19:46 EDT","volume":8116,"amount":26329.85,"timestamp":1781135217325,"change":0.1,"changeRate":0.03125,"amplitude":0.05},"delay":0,"changeRate":-0.05604719764011798,"floatShares":1014390,"shares":1019030,"eps":-241.2,"marketStatus":"Not Yet Opened","change":-0.19,"latestTime":"06-10 16:00:00 EDT","open":3.37,"high":3.52,"low":3.152,"amount":399530.7537804,"amplitude":0.108555,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-241.2,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781164800000},"marketStatusCode":0,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":3.39,"preHourTrading":{"tag":"盘前","latestPrice":3.246,"preClose":3.39,"latestTime":"09:29 EDT","volume":9383,"amount":31557.9771386,"timestamp":1781098171466,"change":-0.144,"changeRate":-0.042478,"amplitude":0.060472},"postHourTrading":{"tag":"盘后","latestPrice":3.3,"preClose":3.2,"latestTime":"19:46 EDT","volume":8116,"amount":26329.85,"timestamp":1781135217325,"change":0.1,"changeRate":0.03125,"amplitude":0.05},"volumeRatio":0.013872},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2641574480","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:26 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641574480","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641574480?lang=en_us&edition=fundamental","pubTime":"2026-06-08 22:26","pubTimestamp":1780928780,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:26 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nAQN2M2JSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117103","title":"Clearmind Medicine spotlights new CMND-100 alcohol use disorder trial data in June 10 webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641117103?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:32","pubTimestamp":1780659144,"startTime":"0","endTime":"0","summary":"Clearmind Medicine scheduled a June 10, 2026 webinar to present new insights from its ongoing Phase I/IIa trial of CMND-100 for alcohol use disorder.Trial data will be discussed in the future during a live investigator Q&A with researchers from Yale and Johns Hopkins.Focus is an update on clinical progress for an oral, non-hallucinogenic MEAI-based candidate, not a product launch or commercial rollout.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLMX8Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4007","BK4585","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","IE00BN0W2W23.USD","CMND","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210149790.SGD","BK4588","LU2095319765.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641171791","title":"Clearmind Medicine to Feature New Insights From Cmnd-100 Psychedelic Clinical Trial on “Inside Meai” Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641171791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641171791?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:32","pubTimestamp":1780659120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUA71DG7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641002117","title":"Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641002117","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641002117?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:32","pubTimestamp":1780659120,"startTime":"0","endTime":"0","summary":"Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live WebinarRegister now for free and joinon June 10, 2026 Vancouver, Canada, June  05, 2026  (GLOBE NEWSWIRE) -- Clea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307314/0/en/Clearmind-Medicine-to-Feature-New-Insights-from-CMND-100-Psychedelic-Clinical-Trial-on-Inside-MEAI-Webinar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964670","title":"Clearmind Medicine to sell $1.5 million in convertible promissory notes at 90% of face value","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964670","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964670?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:12","pubTimestamp":1780344722,"startTime":"0","endTime":"0","summary":"Clearmind Medicine entered a deal to sell $1.5 million of convertible promissory notes to CLA Investors, with closing expected on June 1, 2026.Cash proceeds set at $1.35 million, reflecting a 90% purchase price to principal.The issuance sits within an amended facility to issue up to $10 million of convertible promissory notes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6jSmKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968712","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:27 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968712","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968712?lang=en_us&edition=fundamental","pubTime":"2026-06-01 23:27","pubTimestamp":1780327666,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:27 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAQN2M1J84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640082956","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2640082956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640082956?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:36","pubTimestamp":1780313798,"startTime":"0","endTime":"0","summary":"Mynd.ai (MYND) shares were down 37% in Monday premarket activity, following Friday's 114.5% gain after the company regained compliance with NYSE American's continued listing requirements.Zhongchao (ZC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADTX","OCS","BK4139","ZCMD","BK4007","BK4204","CMND","MYND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639767388","title":"Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan","url":"https://stock-news.laohu8.com/highlight/detail?id=2639767388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639767388?lang=en_us&edition=fundamental","pubTime":"2026-05-29 21:48","pubTimestamp":1780062525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced the publication of a Japanese patent application for its proprietary compositions comprising 5-Methoxy-2-aminoi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-files-japanese-patent-application-for-5-methoxy-2-aminoindan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-files-japanese-patent-application-for-5-methoxy-2-aminoindan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639627421","title":"Clearmind Medicine files Japanese patent application for MEAI-based depression treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2639627421","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639627421?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:35","pubTimestamp":1780058152,"startTime":"0","endTime":"0","summary":"Clearmind Medicine filed a Japanese patent application covering MEAI-based compositions for treating depression.The filing expands the company’s intellectual property portfolio for its flagship non-hallucinogenic neuroplastogen-derived molecule.Clearmind is developing MEAI across additional indications, including alcohol use disorder, weight loss, and other mental disorders.Japan has about 3 million diagnosed cases of major depressive disorder, supporting a sizeable target market for new therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL4zr8tZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638590545","title":"Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638590545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638590545?lang=en_us&edition=fundamental","pubTime":"2026-05-26 22:54","pubTimestamp":1779807267,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that the Johns Hopkins Medicine Institutional Review Board, JHM-IRB, has granted approval for its ongoing Phase...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-jhm-irb-approval-to-advance-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-jhm-irb-approval-to-advance-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638147995","title":"Clearmind says Johns Hopkins IRB clears next stages of CMND-100 Phase I/II trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638147995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638147995?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:25","pubTimestamp":1779798325,"startTime":"0","endTime":"0","summary":"Johns Hopkins Medicine IRB cleared the CMND-100 Phase I/II trial to move into Parts B and C.The multicenter study tests single and multiple doses in healthy volunteers, then Alcohol Use Disorder patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL3yD4Zr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","CMND","LU0314104364.USD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4007","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","SG9999014021.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514201","title":"Clearmind Medicine Announces Johns Hopkins Irb Approval to Advance Cmnd-100 Phase I/Ii Clinical Trial to the Next Parts","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514201?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:25","pubTimestamp":1779798300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUABKZFSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637388102","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 03:58 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2637388102","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637388102?lang=en_us&edition=fundamental","pubTime":"2026-05-21 15:58","pubTimestamp":1779350282,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 03:58 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nAQN2LZWMO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637487459","title":"Clearmind Medicine Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2637487459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637487459?lang=en_us&edition=fundamental","pubTime":"2026-05-21 07:55","pubTimestamp":1779321309,"startTime":"0","endTime":"0","summary":"19:50 EDT Clearmind Medicine (CMND) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853781","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853781","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636853781?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:39","pubTimestamp":1779190766,"startTime":"0","endTime":"0","summary":"WORK Medical Technology  stock was down 38% in Tuesday premarket activity, extending a 42% decline in the previous session.Sagtec Global  shares were 25% lower, extending a 6.4% loss from Monday.Clearmind Medicine  shares were down 32% after the company announced a 1-for-10 reverse stock split.Bitcoin Depot  stock was 24% lower after the company said it initiated a voluntary Chapter 11 process to facilitate a wind-down and sale of assets. The company's shares plunged 73% in the previous session.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAGT","BK4007","BTM","BTM.AU","WOK","BK4023","BTMCQ","BK7095","BK4137","BK7083","BK4198","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858809","title":"Clearmind agrees to convert $600,000 notes into common shares at $0.3 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858809","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636858809?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:52","pubTimestamp":1779187949,"startTime":"0","endTime":"0","summary":"Clearmind Medicine set terms to convert USD 600,000 of outstanding Convertible Notes into common shares.The parties agreed to a fixed conversion price of USD 0.3 per share, overriding the notes’ conversion-price formula.The conversion implies issuance of 2,000,000 common shares, subject to rounding under the notes.The Floor Price definition in the form of Convertible Note under the securities purchase agreement was amended to USD 0.3 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL74cb13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636837792","title":"Clearmind Medicine announces 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2636837792","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636837792?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:10","pubTimestamp":1779185436,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a rati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-1-for-10-reverse-share-split-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-1-for-10-reverse-share-split-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636087832","title":"Clearmind Medicine to execute 1-for-10 reverse stock split May 21","url":"https://stock-news.laohu8.com/highlight/detail?id=2636087832","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636087832?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:02","pubTimestamp":1779184964,"startTime":"0","endTime":"0","summary":"Clearmind Medicine will execute a 1-for-10 reverse share split effective May 21, 2026.The move targets renewed compliance with Nasdaq’s minimum bid price requirement.Issued and outstanding common shares are expected to drop to about 1,019,033 from 10,190,337, with fractional shares rounded up to whole shares.Outstanding options and warrants will be adjusted proportionately for share count and exercise price.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL7mg7js:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4588","IE00BKPKM429.USD","CMND","IE00BN0W2W23.USD","LU2095319765.USD","LU0314104364.USD","BK4585","BK4007","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636832209","title":"BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2636832209","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636832209?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:00","pubTimestamp":1779184850,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share SplitMay 19 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ANNOUNCES 1-FOR-10 REVERSE SHARE SPLITCLEARMIND MEDICINE INC - REVERS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUA4SQZLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636683225","title":"Clearmind Medicine Announces 1-for-10 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2636683225","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636683225?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:00","pubTimestamp":1779184801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUA4SQZLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":0.0997},{"period":"1month","weight":-0.3849},{"period":"3month","weight":-0.6139},{"period":"6month","weight":-0.8923},{"period":"1year","weight":-0.9911},{"period":"ytd","weight":-0.8232}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.137133},{"month":6,"riseRate":0.25,"avgChangeRate":0.033774},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}